Neflamapimod Shows Promise in Slowing Dementia with Lewy Bodies Progression
CervoMed announced positive 16-week results from the extension phase of its Phase 2b RewinD-LB study of neflamapimod for dementia...
Enormous Parkinson’s Breakthrough: Phase 2 Trial Shows Positive Results
AC Immune announced positive interim Phase 2 trial results for ACI-7104.056, an active immunotherapy targeting alpha-synuclein (a-syn) in early...
Connect Biopharma’s Positive Type C Meeting with FDA for Radmikibart
Connect Biopharma announced positive feedback from the FDA regarding its plan for two Phase 2 trials of rademikibart. The...
Microbot Medical Announces Data from ACCESS-PVI Trial at SIR 2024
Microbot Medical announced that data from its ACCESS-PVI trial, evaluating the LIBERTY® Endovascular Robotic System for peripheral vascular interventions,...
Cerevance Unveils Promising Solengepras Phase 2 Results in Parkinson’s
Cerevance announced topline results from its Phase 2 ASCEND trial of solengepras, a non-dopaminergic drug candidate for early-stage, untreated...
Candel Therapeutics Publishes Promising Glioma Trial Data
Candel Therapeutics announced promising Phase 1b clinical trial results for CAN-2409 combined with nivolumab and standard care in newly...
Gene Therapy Trial for Heart Failure Shows Promising Results
Medera Inc. announced updated positive results from its Phase 1/2a clinical trial of SRD-002, a gene therapy for heart...
HYGH-TEC® Balloons Show High Performance and Safety in HYDRA-PMCF Study
Advanced Medical Balloons (AMB) announced positive data from their HYDRA-PMCF study on hygh-tec®, a new polyurethane fecal management system...
Positive Phase 2 Trial Data for Rademikibart in Asthma Patients
Connect Biopharma announced positive Phase 2 trial results for rademikibart, a potential new biologic treatment for moderate-to-severe uncontrolled asthma....
Acoramidis Improves Cardiovascular Outcomes in ATTR-CM Patients
BridgeBio Pharma presented data from a subgroup analysis of its Phase 3 ATTRibute-CM trial, demonstrating acoramidis significantly improved clinical...